Skyrizi (risankizumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It is a subcutaneous injection that is administered by a healthcare provider.

Uses:

Skyrizi is used to treat moderate to severe plaque psoriasis, which is a chronic autoimmune disease that affects the skin. This medication can help reduce scaly and itchy patches on the skin, improve patient quality of life, and slow down the progression of the disease.

HOW TO USE:

Skyrizi should be administered by a healthcare provider as a subcutaneous injection. Patients should not attempt to self-inject without the proper training. The dosage and duration of treatment should be determined by the healthcare provider.

Dosage:

The recommended dosage is 150mg every 12 weeks. The first two doses should be administered four weeks apart.

Mechanism of Action:

Skyrizi works by targeting a protein called interleukin-23 (IL-23), which plays a role in the inflammatory response in psoriasis. By blocking IL-23, Skyrizi can help reduce inflammation, improve skin symptoms, and prevent further progression of the disease.

Storage Conditions:

Skyrizi should be refrigerated at 2°C to 8°C and should be protected from light. The medication can be administered at room temperature if left at room temperature for no more than 30 days.

Precautions:

• Skyrizi can increase the risk of infections, including tuberculosis and fungal infections. Patients should be screened for tuberculosis before starting treatment and should not receive live vaccines while taking Skyrizi.
• Patients should inform their healthcare provider if they have a history of inflammatory bowel disease before starting treatment with Skyrizi.
• Use with caution in patients with a history of recurrent infections.

Interactions:

• Skyrizi may interact with certain medications that suppress the immune system, such as corticosteroids and other biologic medications. Patients should inform their healthcare provider of all medications they are taking before starting treatment with Skyrizi.

Contraindications:

• Skyrizi is contraindicated in patients with a history of severe allergic reaction to risankizumab or any of its components.

Side Effects:

The most common side effects of Skyrizi include upper respiratory tract infection, headache, fatigue, injection site reactions, and fungal infections. Serious adverse events are rare, but some patients may experience unexpected reactions or allergic responses. Patients should inform their healthcare provider of any unusual reactions while taking Skyrizi.

Overdose:

There are no reported cases of overdose associated with Skyrizi.

In conclusion, Skyrizi (risankizumab) is a subcutaneous injection used to treat moderate to severe plaque psoriasis in adults. The recommended dosage is 150mg every 12 weeks, with the first two doses administered four weeks apart. Skyrizi blocks interleukin-23, reducing inflammation and improving skin symptoms. It should be stored at 2-8°C and is contraindicated in patients with a history of severe allergic reaction to risankizumab. Patients should be screened for tuberculosis and monitored for infections and potential allergic reactions. The most common side effects include upper respiratory tract infection, headache, fatigue, and injection site reactions. Serious adverse events are rare, and no cases of overdose have been reported.